GI Colorectal / Rectal Cancer (CRC)

Localised

Colon
- Adjuvant
- Neoadjuvant / Adjuvant

Anal (Squamous Cell)
- Adjuvant
- Neoadjuvant / Adjuvant

Rectal

Non-Intervention CRC

Metastatic CRC

1st Line
- 1st Line Metastatic CRC

2nd Line
- 2nd Line Metastatic CRC

3rd Line
- 3rd Line Metastatic CRC

Beyond 3rd Line HER2+

Adjuvant

Metastatic Anal

IRB# 21658
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

IRB# 22465
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

IRB# 19296
A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of afollitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer

IRB# 20747
A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

IRB# 20980
Immunotherapy during neoadjuvant therapy for rectal cancer, a phase II randomized multi-center trial with and without APX005M, an anti-CD40 agonist

IRB# 21972
A Phase 3 Study to Evaluate the Efficacy and Safety of Olaparib Alone Or In Combination With Bevacizumab Compared To Bevacizumab With 5-Fu in Participants With Unresectable Or Metastatic Colorectal Cancer Who Have Not Progressed Following First-Line Induction Of FOLFOX With Bevacizumab

CROSS-DISEASE TRIALS:

IRB# TBD
EAY131 (MATCH)

IRB# 20075 [NCI CIRB] EA2165 - A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

IRB# 19576
Phase 1B Study to Assess the Safety of Neoadjuvant TAS-102 (Lonsurf) with Concurrent Radiation in Previously Untreated Rectable Stage II and Stage III Rectal Cancer

IRB# 20980
Immunotherapy during neoadjuvant therapy for rectal cancer, a phase II randomized multi-center trial with and without APX005M, an anti-CD40 agonist

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

3/1/2021

http://www.ohsu.edu/research/rda/so/knight.php